There were 16 acquisitions of companies with small molecule drug assets in 2021 and one merger. Here is a more in-depth look into all of the lead small molecules acquired in 2021, including a review of:
- The lead molecules in each acquisition and their structural representations where disclosed
- The mechanism of action, stage, and indication of each lead molecule
- Relevant clinical data and rationale for each acquisition
this content is exclusive to
Unlock this content with a Premium membership to read it now.